Identity
- Security key
- 20095
- Ticker
- PHAT
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2019-10-25
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- PHAT
Detail
Enriched 2026-08-14 20:47
- Market cap
- $741,861,564.78
- Shares outstanding (class)
- 80,900,934
- Shares outstanding (weighted)
- 80,900,934
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 371
- Location
- FLORHAM PARK, NJ
- Homepage
- https://www.phathompharma.com
- Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Market cap and share counts drift.